The prescription market for idiopathic (immune) thrombocytopenia treatments is expected to grow exponentially with the recent reimbursement standard extension granted in Korea.

Until now, reimbursement for oral immune thrombocytopenia drugs has been limited to patients with immune thrombocytopenia who are refractory to corticosteroids and immunoglobulins after splenectomy or are refractory to corticosteroids and immunoglobulins and have medical contraindications to splenectomy.

However, as of next month, the current reimbursement standards that require 'splenectomy' will be changed, and the oral drug will be available for use upon just the diagnosis of the disease, which is expec